<DOC>
	<DOCNO>NCT01621217</DOCNO>
	<brief_summary>- To establish maximum tolerate dose two cytotoxic drug 5-fluoruracil mitomycin C give together antibody cetuximab patient locally advanced cancer anal region - To evaluate acute toxicity - To evaluate late toxicity - To evaluate response rate - To evaluate recurrence free survival - To evaluate overall survival</brief_summary>
	<brief_title>Phase I Study Cetuximab Combination With 5-fluoruracil , Mitomycin C Radiotherapy Patients With Anal Cancer Stage T2 ( &gt; 4 cm ) - T4 N0-3 M0 Any T N2-3 M0</brief_title>
	<detailed_description />
	<mesh_term>Anus Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<mesh_term>Mitomycin</mesh_term>
	<mesh_term>Mitomycins</mesh_term>
	<criteria>Age 18 year Histologically cytologically confirm squamous cell cancer anal region ( anal canal anal margin distal rectum ) Stage T2 ( ≥4 cm ) T4 N03 M0 T N23 M0 ECOG performance status 01 Hb &gt; 100 g/L ANC &gt; 1.5 x 10 9/L Platelets ≥ 100 x 10 9/L Creatinine &lt; 1.5 x ULN Bilirubin &lt; 1.5 x ULN ALAT &lt; 3.0 x ULN Competent comprehend , sign date approve informed consent form Previous pelvic irradiation Previous chemotherapy anal cancer Previous malignancy within last 5 year , except curatively treat nonmelanoma skin cancer carcinoma situ cervix uteri Pregnant nursing female patient childbearing potential use adequate method birth control Patients active infection serious underlie medical condition , would impair ability patient receive protocol treatment Known hypersensitivity component treatment Clinically significant cardiovascular disease , e.g . cardiac failure ( &lt; 12 month treatment start ) , unstable angina , congestive heart failure , arrythmia require medication , uncontrolled hypertension Known positive test hepatitis C virus , chronic active hepatitis B infection Known HIV infection Any condition therapy investigator´s opinion may pose risk patient interfere study objective Any investigational agent within 30 day enrolment Surgery ( exclude diagnostic biopsy central venous catheter placement ) and/or radiotherapy within 28 day prior inclusion study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Anal cancer</keyword>
	<keyword>Locally advanced anal cancer</keyword>
	<keyword>Cetuximab</keyword>
	<keyword>5-fluoruracil</keyword>
	<keyword>Mitomycin C</keyword>
	<keyword>Radiotherapy</keyword>
</DOC>